# Foundayo vs Tirzepatide: Pill vs Shot, Compared

**By TelosRX Editorial Team** · 2026-11-11

**Foundayo vs tirzepatide is pill vs shot. Foundayo is a daily GLP-1 tablet. Tirzepatide is a weekly GIP/GLP-1 injection with larger average weight loss in trials. [TelosRX](https://telosrx.com) compares both, side by side.**

Foundayo vs tirzepatide is the newest matchup in weight-loss medicine. Searches for it jumped after Foundayo's approval this year. Both come from the same drugmaker. They work in related ways. But they fit very different routines.

This guide compares the two on mechanism, dosing, trial results, side effects and daily life. It is educational, not personal advice. Any prescription is subject to medical approval by a licensed provider.

## Foundayo vs Tirzepatide: The Short Answer

**Foundayo** is the brand name for orforglipron. It's a once-daily pill. It acts on one gut-hormone receptor, GLP-1.

**Tirzepatide** is sold as Zepbound and Mounjaro. It's a once-weekly injection. It acts on two receptors, GIP and GLP-1.

In separate trials, tirzepatide produced more average weight loss. Foundayo wins on convenience: no needles and no food timing rules. There is no published head-to-head trial between them yet.

## Head-to-Head Comparison Table

| Factor | Foundayo (orforglipron) | Tirzepatide (Zepbound, Mounjaro) |
| --- | --- | --- |
| Form | Oral tablet | Injection under the skin (pen or vial) |
| How often | Once daily | Once weekly |
| Receptors targeted | GLP-1 only | GIP and GLP-1 |
| Molecule type | Small molecule (not a peptide) | Peptide |
| Food rules | With or without food, any time of day | With or without food, same day each week |
| Starting dose | 0.8 mg daily | 2.5 mg weekly |
| Top dose | 17.2 mg daily | 15 mg weekly |
| Step-up pace | At least 30 days per step | At least 4 weeks per step |
| 72-week trial result (top dose) | About 11% average loss vs about 2% placebo | About 21% average loss vs about 3% placebo |
| FDA-approved uses | Chronic weight management in eligible adults | Weight management and obstructive sleep apnea (Zepbound); type 2 diabetes (Mounjaro) |
| Boxed warning | Thyroid C-cell tumors | Thyroid C-cell tumors |
| Birth control pill note | Back-up method for 30 days after start and each increase | Back-up method for 4 weeks after start and each increase |

Trial figures come from different studies with different people. Compare them with care. Individual results vary.

## What Is Foundayo?

Foundayo (orforglipron) is a GLP-1 receptor agonist pill from Eli Lilly. The FDA approved it in April 2026. It is used with a reduced-calorie diet and more physical activity in adults with obesity, or overweight plus a weight-related condition.

Here's the twist. Most GLP-1 drugs are peptides, which the gut breaks down easily. Orforglipron is a small molecule instead. That's why it survives digestion without strict empty-stomach rules.

The full details are in the [FDA prescribing information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf).

## What Is Tirzepatide?

Tirzepatide is a dual agonist. It mimics two incretin hormones (gut hormones released after meals): GIP and GLP-1. Together they slow stomach emptying, boost fullness and help regulate blood sugar.

It's sold under two brand names. Zepbound is approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. Mounjaro is approved for type 2 diabetes.

Already confused about the brand names? Our explainer on [whether Zepbound is the same as tirzepatide](https://www.telosrx.com/blogs/glp1/is-zepbound-the-same-as-tirzepatide) clears it up.

## How They Work Differently

Both drugs act on the GLP-1 receptor. That's the shared core. It signals fullness to the brain and slows how fast food leaves the stomach.

-   **Foundayo:** one target, GLP-1. Taken daily, so blood levels stay fairly steady.
-   **Tirzepatide:** two targets, GIP plus GLP-1. Researchers think the GIP signal adds to fullness and may improve tolerability.
-   **Delivery:** a pill must be absorbed through the gut. An injection skips digestion entirely.

That second receptor is the main reason experts expect tirzepatide to lead on average weight loss.

## Weight-Loss Results From the Trials

Neither drug has been tested against the other directly. So the best comparison is each drug against placebo, over a similar 72 weeks.

-   **Foundayo (ATTAIN-1):** adults without diabetes lost about 11% of body weight on average at the top dose. Placebo averaged about 2% ([Wharton et al., NEJM, 2025](https://www.nejm.org/doi/full/10.1056/NEJMoa2511774)). The FDA label reports a placebo-adjusted difference of about 9% at 17.2 mg.
-   **Tirzepatide (SURMOUNT-1):** adults without diabetes lost about 15% to 21% on average, depending on dose. Placebo averaged about 3% ([Jastreboff et al., NEJM, 2022](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038)).

Averages hide a wide range. Some people respond strongly to either drug. Others respond less. Individual results vary, and no result is guaranteed.

## Dosing and Daily Routine

This is where the two feel most different day to day.

### Foundayo dosing

1.  Start at 0.8 mg once daily for at least 30 days.
2.  Step up to 2.5 mg, then 5.5 mg, each after at least 30 days.
3.  Your prescriber may move to 9 mg, 14.5 mg or 17.2 mg based on response and tolerability.
4.  Swallow whole. Take it with or without food.
5.  Missed seven or more days in a row? The label says to restart at a lower dose.

### Tirzepatide dosing

1.  Start at 2.5 mg once weekly for 4 weeks.
2.  Increase by 2.5 mg steps, at least 4 weeks apart.
3.  Maintenance doses range from 5 mg to 15 mg weekly.
4.  Inject on the same day each week, rotating sites.

A pill means one small habit every day. A shot means one bigger habit once a week. Neither is better. It's about which you'll actually stick with.

## Side Effects Compared

Both drugs share the classic GLP-1 side-effect list. Most are digestive and show up during dose increases.

-   Nausea
-   Diarrhea
-   Constipation
-   Vomiting
-   Indigestion and burping
-   Stomach pain

In Foundayo's label, nausea affected 35% at the 17.2 mg dose, vs 10% on placebo. Vomiting affected 24%, vs 4% on placebo. Tirzepatide's labels list a similar pattern of digestive effects.

Both carry the same boxed warning about thyroid C-cell tumors seen in rodent studies. Neither should be used with a personal or family history of medullary thyroid carcinoma or MEN 2. Rarer risks on both labels include pancreatitis, gallbladder problems and kidney strain from dehydration.

Want practical tips? Our step-by-step guide to [managing oral GLP-1 side effects](https://www.telosrx.com/blogs/glp1/wegovy-pill-side-effects-how-to-manage) applies to most daily pills.

## Drug Interactions and Birth Control

Both drugs slow stomach emptying. That can change how other pills absorb, including oral birth control.

-   **Foundayo:** use a non-oral method or add a barrier method for 30 days after starting and after each dose increase.
-   **Tirzepatide:** the same idea, for 4 weeks after starting and after each increase.
-   **Foundayo extra:** it's processed by liver enzymes, so several common medicines can raise or lower its levels. Share your full medication and supplement list.

Never take the two together. They overlap in action and would stack side effects.

## Which Should You Consider?

There's no universal winner. Here's how the trade-offs usually shake out.

-   **You may lean toward Foundayo if** you strongly prefer a pill, dislike needles, or want no food-timing rules.
-   **You may lean toward tirzepatide if** the larger average trial results matter most, or you prefer a once-weekly routine.
-   **Either way,** your health history, other medications and goals decide fit. That's a provider's call.

Curious whether tirzepatide fits you? [Explore the TelosRX tirzepatide program](https://www.telosrx.com/pages/tirzepatide). Compounded tirzepatide is not FDA-approved, and access is subject to medical approval by a licensed provider through our asynchronous online review.

## Switching Between a Shot and a Pill

Many people ask about moving from a weekly shot to a daily pill. Lilly has reported phase 3 data on people switching from injectable incretin drugs to orforglipron for weight maintenance. Results were shared by the company and should be read alongside peer-reviewed publications as they appear.

Switching changes your dose ladder and side-effect risk. Never switch on your own. Your provider sets the new starting point.

Comparing other GLP-1 matchups? See [tirzepatide vs semaglutide side effects](https://www.telosrx.com/blogs/glp1/tirzepatide-vs-semaglutide-side-effects), or [compare TelosRX GLP-1 options](https://www.telosrx.com/pages/glp-1-options).

## Frequently Asked Questions

### Is Foundayo the same as tirzepatide?

No. Foundayo is orforglipron, a once-daily oral GLP-1 pill. Tirzepatide is a once-weekly injection sold as Zepbound and Mounjaro that acts on both GIP and GLP-1 receptors. Both are made by Eli Lilly, which is why they are often confused, but they are different molecules with different dosing.

### Which causes more weight loss, Foundayo or tirzepatide?

In separate 72-week trials, tirzepatide produced more average weight loss, about 15% to 21% depending on dose, compared with about 11% at Foundayo's highest dose. The two have not been compared head to head. Individual results vary, and the right choice depends on your health history.

### Do you have to take Foundayo on an empty stomach?

No. According to the FDA label, Foundayo can be taken once daily with or without food, at any time of day. Swallow the tablet whole without crushing or chewing. This is a key difference from the Wegovy pill, which has strict empty-stomach timing rules.

### What are the most common Foundayo side effects?

The most common Foundayo side effects are digestive: nausea, diarrhea, constipation, vomiting, indigestion, stomach pain and burping. They are most likely during dose increases. The label also lists a boxed warning for thyroid C-cell tumors and rarer risks such as pancreatitis and gallbladder problems.

### Can you switch from tirzepatide to Foundayo?

Switching may be possible, but only under a provider's direction. Your provider decides the new starting dose and monitors side effects. Lilly has reported phase 3 data on people moving from injectable incretin drugs to orforglipron for weight maintenance, but individual results vary.

### Can you take Foundayo and tirzepatide together?

No. Both drugs activate the GLP-1 receptor, so combining them would overlap their effects and raise the risk of side effects such as nausea, vomiting and dehydration. If one medication is not working well enough, talk with your provider about adjusting the plan rather than stacking drugs.

_TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service._

Start your private evaluation at [TelosRX](https://telosrx.com).

**Tags:** comparison, Foundayo vs tirzepatide, oral GLP-1, orforglipron, tirzepatide, Zepbound

---

> Source: [Telos RX](https://www.telosrx.com/blogs/glp1/foundayo-vs-tirzepatide-comparison)
